Welcome to IRESSA.com, an international resource provided by AstraZeneca for health care professionals interested in lung cancer and IRESSA (gefitinib).

Features

Phase III INTEREST study reported at WCLC, 5th September 2007, Seoul, Korea Treatment options: A review of the therapeutic options available for lung cancer including information about EGFR tyrosine kinase inhibitors	Disease information: A review of the risk factors, anatomy, physiology and pathology of lung cancer About IRESSA (gefitinib): Review a list of countries in which IRESSA is available.
IRESSA is a trade mark of the AstraZeneca group of companies. This site is intended to provide information to Health Care Professionals outside the USA. If you are a patient or caregiver, please visit patients & carers